An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

Trial Profile

An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational
  • Sponsors Amgen
  • Most Recent Events

    • 02 Mar 2017 Status changed from completed to active, no longer recruiting.
    • 15 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 04 Nov 2016 According to Amgen media release, the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL (etanercept) to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis based on the results of this trial and phase 3 PEDS trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top